Literature DB >> 29435735

Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.

Takuya Ueda1,2,3,4, Keiju Aokage2, Hiroyoshi Nishikawa5, Shinya Neri6, Hiroshi Nakamura1,3,4, Masato Sugano3, Kenta Tane2, Tomohiro Miyoshi2, Motohiro Kojima1, Satoshi Fujii1, Takeshi Kuwata3, Atsushi Ochiai7, Masahiko Kusumoto8, Kenji Suzuki4, Masahiro Tsuboi2, Genichiro Ishii9.   

Abstract

PURPOSE: Patients with usual interstitial pneumonia (UIP) often develop lung cancer. However, the biological features of lung cancer associated with UIP remain unknown. The aim of this study was to elucidate the clinicopathological characteristics of UIP-associated squamous cell carcinoma (SqCC).
METHODS: A total of 244 patients with p-stage I lung SqCC who underwent complete surgical resection were enrolled in this study. Clinicopathological differences between UIP-associated SqCC and non-UIP SqCC were examined. Moreover, we performed immunohistochemical studies to clarify the biological differences between these two groups.
RESULTS: UIP-associated SqCC was detected in 19 patients (6.0%). Patients with UIP-associated SqCC tended to have shorter recurrence-free survival (RFS) (5-year RFS; UIP-associated SqCC 44% vs non-UIP SqCC 62%, p = 0.05). Immunohistochemical analysis revealed that the expression scores of cancer stem cell- and invasion-related molecules in cancer cells were not significantly different between the two groups. However, PD-L1 expression in cancer cells was significantly higher in UIP-associated SqCC (median score; 5.0 vs 0, p < 0.01). In the stroma of UIP-associated SqCC, the number of Foxp3+ tumor-infiltrating lymphocytes was significantly higher than that in non-UIP SqCC (median number 43/HPF vs 24/HPF, p < 0.01). In addition, CD8+/Foxp3+ T-cell ratio in UIP-associated SqCC was significantly lower than that in non-UIP SqCC (median ratio 1.8 vs 3.4, p < 0.01).
CONCLUSION: Our current study clearly revealed that the establishment of an immunosuppressive tumor microenvironment is a characteristic feature of UIP-associated SqCC, which can be correlated with poor prognosis in UIP-associated SqCC.

Entities:  

Keywords:  Lung squamous cell carcinoma; PD-L1; Tumor immunity; Tumor microenvironment; Usual interstitial pneumonia

Mesh:

Substances:

Year:  2018        PMID: 29435735     DOI: 10.1007/s00432-018-2602-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Lung cancer associated with usual interstitial pneumonia.

Authors:  H Matsushita; S Tanaka; Y Saiki; M Hara; K Nakata; S Tanimura; J Banba
Journal:  Pathol Int       Date:  1995-12       Impact factor: 2.534

2.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

3.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

4.  Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

Authors:  Xin Chen; Jeffrey J Subleski; Heather Kopf; O M Zack Howard; Daniela N Männel; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 5.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

6.  The impact of lung cancer on survival of idiopathic pulmonary fibrosis.

Authors:  Sara Tomassetti; Christian Gurioli; Jay H Ryu; Paul A Decker; Claudia Ravaglia; Paola Tantalocco; Matteo Buccioli; Sara Piciucchi; Nicola Sverzellati; Alessandra Dubini; Giampaolo Gavelli; Marco Chilosi; Venerino Poletti
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

7.  Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Authors:  A F Olumi; G D Grossfeld; S W Hayward; P R Carroll; T D Tlsty; G R Cunha
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

8.  Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Kevin Gibson; José Cisneros; Thomas J Richards; Yinke Yang; Carina Becerril; Samueal Yousem; Iliana Herrera; Victor Ruiz; Moisés Selman; Naftali Kaminski
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

9.  Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).

Authors:  Qinxiang Guo; Yu Sun; Sifan Yu; Hua Bai; Jun Zhao; Minglei Zhuo; Jie Wang
Journal:  Thorac Cancer       Date:  2016-12-23       Impact factor: 3.500

Review 10.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more
  2 in total

Review 1.  Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.

Authors:  Beatriz Ballester; Javier Milara; Julio Cortijo
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

Review 2.  Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?

Authors:  Sara Lettieri; Tiberio Oggionni; Andrea Lancia; Chandra Bortolotto; Giulia Maria Stella
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.